ESG Is Now a Leadership Competency. Are You Hiring for It?

Let's start with an uncomfortable truth.

When ESG first entered the conversation in life sciences boardrooms, many leadership teams treated it as a compliance exercise. A reporting framework. Something for the sustainability team to manage and the communications team to package.

Those days are over.

For executive search firms and VC talent managers operating in life sciences, ESG has become one of the most consequential forces shaping who gets hired, who gets funded, and which organizations attract the leadership talent capable of building enduring companies.

As PwC’s Health Research Institute put it directly:

“Many pharmaceutical and life science companies have the opportunity to move beyond platitudes to build action-oriented ESG efforts throughout their business — from supply chains to environmental footprint, clinical trial diversity to executive leadership composition.”

If you are not fluent in this, you are already behind.

Why Life Sciences Is Not Like Every Other Sector

ESG matters in every industry, but in life sciences, it hits differently. This is a sector built entirely around human health. You can't separate the mission from the business model; the E, the S, and the G are baked into the very reason these companies exist.

Consider:

• A pharmaceutical company that pollutes water systems while developing medicines to treat disease is not a paradox. It is a credibility crisis.

• A biotech that cannot demonstrate workforce diversity while claiming to develop therapies for underserved populations will rightly face increasingly hard questions from investors, regulators, and patients.

• A medical device company with governance failures that reach the board will find that the FDA, institutional investors, and potential acquirers are all paying attention simultaneously.

  
  

In life sciences, ESG failures are not reputational problems. They are existential threats.

Our industry has a significant footprint, we need to take responsibility.

Breaking Down What ESG Actually Means

Environmental — The Underestimated E

Life sciences has a significant environmental footprint that the industry has been slow to reckon with. And the data is now emerging to make it clear .

Scope 3 emissions — those generated across the value chain rather than directly by the company — the figures vary depending on the source, however Life sciences has a significant environmental footprint that the industry has been slow to reckon with. And the data is now too clear to ignore.

Scope 1 and 2 emissions are declining meaningfully among leading biotech and pharmaceutical companies, and top performers are beginning to record measurable year‑on‑year reductions in Scope 3 as well. A growing majority of large players now disclose emissions across all three scopes, improving transparency and accountability

And critically, ambition is rising rather than retreating.

What does this mean for the talent market? Companies aren't looking for figureheads anymore. They need executives who understand green chemistry, sustainable manufacturing, and how to decarbonize a supply chain without delaying a launch.

A Chief Sustainability Officer in life sciences can't just be a communications specialist. They have to be an operational leader who understands science, manufacturing, and regulatory affairs. Finding people who can hit net-zero targets without compromising product quality is incredibly tough—but that’s the new baseline.

Social — The S That Carries the Most Complexity

The social dimension is arguably the most complex part of the equation for our industry, touching every part of the business.

Access and affordability remain the most politically and commercially charged issues in the industry. Pricing decisions, access programs, and health equity strategies are now scrutinized by investors, payers, patient advocacy groups, and legislators simultaneously. The executive who cannot speak credibly and specifically to this is increasingly a liability.

Clinical trial diversity has moved from an ethical aspiration to a regulatory expectation. The FDA has made its position clear. Investors and partners are asking hard questions. Companies that cannot demonstrate diverse trial populations face both scientific credibility challenges — because homogeneous trial data has real generalizability limitations — and ESG scoring consequences that affect their cost of capital.

Leading organizations are responding. As PwC notes, companies are now:

“Expanding data collection efforts to better report on societal racial inequities in outcomes and the steps they are taking to address them.”

This is measurement and accountability language. It signals that the S in ESG is becoming as structured and reportable as financial performance.

DEI Matters

Workforce equity matters here as it does everywhere, but with added complexity. Life sciences has a well-documented diversity problem in senior leadership that sits awkwardly alongside an industry narrative of improving human lives. The gap between the patient populations these companies serve and the leadership teams making decisions about their care is a vulnerability that sophisticated investors and talent increasingly notice.

What this means for talent: The executives who can hold commercial pressure, scientific integrity, regulatory expectation, and genuine social mission in the same frame — without compromising any of them — are the ones your clients most need and are hardest to find.

Governance — The G That Determines Whether Any of It Is Real

Governance is the foundation that proves whether any of this is real. Reporting is maturing fast. Companies are moving toward frameworks like GRI and SASB, showing that structured governance is the new normal.

In life sciences, governance failures have a recognizable pattern:

• Boards that lack scientific literacy making consequential R&D decisions

• Compensation structures that incentivize short-term commercial performance over long-term pipeline health

• Risk management frameworks that do not account adequately for regulatory, clinical, or reputational exposure

• Conflicts of interest in clinical research relationships and KOL management

• Data integrity failures that cascade from laboratory to regulatory submission

  
  

What this means for talent: Board composition in life sciences is under greater scrutiny than at any point in the industry’s history. Institutional investors, proxy advisory firms, and increasingly the FDA itself are looking at whether boards have the scientific, commercial, and ethical competence to govern these organizations effectively.

For executive search firms, this creates a specific mandate: the ability to identify and place board directors who bring genuine domain expertise, independence of thought, and governance sophistication — not just prestigious names.

For VC talent managers, it means building governance infrastructure early in a portfolio company’s life, before the pressure of a public offering or partnership negotiation forces the issue.

How ESG Is Reshaping the Talent Market

The Investor Lens Has Shifted

Institutional investors — and increasingly sophisticated VC funds — are integrating ESG assessments into their investment and portfolio management decisions.

This means:

• Leadership teams are being evaluated on ESG competency alongside financial performance

• Portfolio companies with weak ESG profiles face a higher cost of capital

• M&A diligence now routinely includes ESG assessment of target leadership teams and governance structures

  
  

If your clients are preparing for an exit, their leadership team’s ESG credentials are part of the valuation story.

Talent Is Voting With Its Feet

The most capable scientific and commercial leaders in life sciences have options. Increasingly, they are exercising those options in favour

of organizations whose ESG commitments they find credible.

This is particularly pronounced among:

• Senior scientists who have built careers around mission-driven research

• Commercial leaders who have come through patient advocacy or access roles

• The generation of executives now moving into their peak leadership years who have watched greenwashing erode trust and have no interest in being part of it

  
  

Authentic ESG commitment is a talent acquisition and retention strategy. Companies that understand this are building cultures that attract better people. Companies that do not are finding their talent pipelines narrowing in ways they have not yet fully understood.

Regulatory Pressure Is Accelerating

The SEC’s climate disclosure rules, the EU’s Corporate Sustainability Reporting Directive, and evolving FDA guidance on health equity and trial diversity are creating a compliance landscape that requires executive competency — not just legal and compliance team management.

CEOs and CFOs who cannot engage substantively with ESG reporting requirements are becoming liabilities.

This raises the specification for every senior executive search you are running.

What This Means for How We Search

For executive search professionals and VC talent managers in life sciences, ESG literacy needs to become part of the core framework — not an addendum.

In candidate assessment:

• Probe specifically for ESG track record, not just awareness

• Ask for concrete examples of how candidates have navigated the tension between commercial pressure and ESG commitments

• Assess whether their understanding of the issues is substantive or rhetorical

In client briefings:

• Help clients articulate what ESG leadership means for their specific stage, therapeutic area, and investor base

• Push back when ESG requirements are vague or performative

• Build ESG competency into the role specification from the beginning, not as an afterthought

In market mapping:

• Recognize that the pool of executives with genuine ESG credentials in life sciences is smaller than clients assume

• Identify emerging talent who have built ESG expertise in adjacent industries — sustainability, healthcare policy, patient advocacy — who can bring fresh thinking

• Understand that diversity of leadership team composition is itself an ESG metric your clients are being measured on

The Big Conversation We Need to Have

None of this is easy.

There is genuine tension between the capital intensity of drug development and the expectations of sustainable investing. There is complexity in pricing and access debates that does not resolve neatly. There is a risk of ESG becoming a reporting exercise that consumes organizational energy without changing behaviour.

And there is greenwashing — companies that have learned to speak the ESG language fluently while the underlying practices remain unchanged.

The most valuable thing we can offer our clients is the ability to tell the difference.

Between executives who have genuinely led ESG transformation and those who have learned to narrate it. Between governance structures that have real integrity and those that have the appearance of it. Between companies building authentic ESG capability and those managing an impression.

That discernment — applied rigorously in search, assessment, and talent strategy — is where we create real value.

Where This Is Going

This isn't a passing trend. Climate risks, health equity, and investor scrutiny are permanent structural shifts. The life sciences companies that build real ESG capability into their leadership teams now will win the race for capital, talent, and trust. The rest will fall behind.

As talent partners, the decisions we make today will shape the leadership of this industry for the next decade. Let’s make sure we’re getting it right.

I’d love to hear how these dynamics are playing out in your current searches. Let's connect and discuss how we can navigate this shifting landscape together.

References

PwC Health Research Institute (HRI). “How health organizations can integrate ESG priorities.” PwC US, Health Industries Library ESG for health organizations